These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37992785)

  • 1. Activin A targets extrasynaptic NMDA receptors to ameliorate neuronal and behavioral deficits in a mouse model of Huntington disease.
    Nassrallah WB; Ramandi D; Cheng J; Oh J; Mackay J; Sepers MD; Lau D; Bading H; Raymond LA
    Neurobiol Dis; 2023 Dec; 189():106360. PubMed ID: 37992785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
    Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
    Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice.
    Dau A; Gladding CM; Sepers MD; Raymond LA
    Neurobiol Dis; 2014 Feb; 62():533-42. PubMed ID: 24269729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.
    Kolodziejczyk K; Raymond LA
    Neurobiol Dis; 2016 Feb; 86():62-74. PubMed ID: 26621114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
    Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
    J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
    Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
    Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.
    Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I
    J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
    Starling AJ; André VM; Cepeda C; de Lima M; Chandler SH; Levine MS
    J Neurosci Res; 2005 Nov; 82(3):377-86. PubMed ID: 16211559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restored Fyn Levels in Huntington's Disease Contributes to Enhanced Synaptic GluN2B-Composed NMDA Receptors and CREB Activity.
    Fão L; Coelho P; Rodrigues RJ; Rego AC
    Cells; 2022 Sep; 11(19):. PubMed ID: 36231023
    [No Abstract]   [Full Text] [Related]  

  • 11. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease.
    Li L; Murphy TH; Hayden MR; Raymond LA
    J Neurophysiol; 2004 Nov; 92(5):2738-46. PubMed ID: 15240759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.
    Ryskamp D; Wu J; Geva M; Kusko R; Grossman I; Hayden M; Bezprozvanny I
    Neurobiol Dis; 2017 Jan; 97(Pt A):46-59. PubMed ID: 27818324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
    Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
    BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMDA receptor function in mouse models of Huntington disease.
    Cepeda C; Ariano MA; Calvert CR; Flores-Hernández J; Chandler SH; Leavitt BR; Hayden MR; Levine MS
    J Neurosci Res; 2001 Nov; 66(4):525-39. PubMed ID: 11746372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
    Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA
    J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early TNF-Dependent Regulation of Excitatory and Inhibitory Synapses on Striatal Direct Pathway Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease.
    Chambon J; Komal P; Lewitus GM; Kemp GM; Valade S; Adaïdi H; Al Bistami N; Stellwagen D
    J Neurosci; 2023 Jan; 43(4):672-680. PubMed ID: 36517241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model.
    Gladding CM; Sepers MD; Xu J; Zhang LY; Milnerwood AJ; Lombroso PJ; Raymond LA
    Hum Mol Genet; 2012 Sep; 21(17):3739-52. PubMed ID: 22523092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GluN3A promotes NMDA spiking by enhancing synaptic transmission in Huntington's disease models.
    Mahfooz K; Marco S; Martínez-Turrillas R; Raja MK; Pérez-Otaño I; Wesseling JF
    Neurobiol Dis; 2016 Sep; 93():47-56. PubMed ID: 27072890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease.
    Shehadeh J; Fernandes HB; Zeron Mullins MM; Graham RK; Leavitt BR; Hayden MR; Raymond LA
    Neurobiol Dis; 2006 Feb; 21(2):392-403. PubMed ID: 16165367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.
    Gladding CM; Fan J; Zhang LY; Wang L; Xu J; Li EH; Lombroso PJ; Raymond LA
    J Neurochem; 2014 Jul; 130(1):145-59. PubMed ID: 24588402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.